A study evaluating the safety and effectiveness of Sacituzumab Govitecan with or without Pembrolizumab in metastatic HR+/HER2- breast cancer.
Brief description of study
The research study procedures include: screening for eligibility, research blood collections, at least two research biopsies, paired research stool collections, and study treatment including evaluations and follow up visits.
Eligibility of study
You may be eligible for this study if you meet the following criteria:
-
Conditions:
breast cancer
-
Age: Between 18 Years - 99 Years
-
Gender: All
Male and Female, Age 18 or older, Diagnosis of breast cancer
Updated on
09 Mar 2024.
Study ID: 850029
Find a site
,
You have contacted , on
Your message has been sent to the study team at ,
A copy of the message has been sent to your email
What happens next?
- You can expect the study team to contact you via email or phone in the next few days.
- Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.
You are contacting